Latest news with #Therapeutics
Globe and Mail
a day ago
- Business
- Globe and Mail
Multiple Sclerosis Pipeline Landscape Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook Key Takeaways from the Multiple Sclerosis Pipeline Report In July 2025, Novartis Pharmaceuticals announced a study is divided into a Core Part and Extension Part. The Core Part is a 24-month, double-blind, triple dummy, randomized, 3-arm active-controlled in children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The Extension Part is 60-month (5 year) open label (except for first 12 weeks transition which will remain double-blind) treatment for patients who complete the Core Part of the study and meet all inclusion/exclusion criteria. In July 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment. The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment Multiple sclerosis Emerging Drugs Profile IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. BIIB091: Biogen BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis. IMCY-0141: ImCyse IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis. NeuroVax: Immune Response BioPharma NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients. The Multiple Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment. Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs Multiple Sclerosis Companies Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Multiple Sclerosis Pipeline Report Coverage- Global Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies Table of Content Introduction Executive Summary Multiple sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Multiple sclerosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BIIB091: Biogen Drug profiles in the detailed report….. Early Stage Products (Phase I) NeuroVax: Immune Response BioPharma Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Multiple sclerosis Key Companies Multiple sclerosis Key Products Multiple sclerosis- Unmet Needs Multiple sclerosis- Market Drivers and Barriers Multiple sclerosis- Future Perspectives and Conclusion Multiple sclerosis Analyst Views Multiple sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yahoo
2 days ago
- Business
- Yahoo
Illimis secures funding for GAIA-based Alzheimer's therapeutics
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor (GAIA)-based Alzheimer's disease therapeutics. The round saw participation from eight existing investors, including Woori Venture Partners, DSC Investment, Korea Development Bank and Quad Asset Management. Joining them were 10 new supporters such as LB Investment and TS Investment. The company also plans to utilise these funds to extend its research into immune disorders and enhance its portfolio with more potential blockbuster drugs. Its GAIA platform aims to leverage the therapeutic potential of Tyro3, Axl, Mer (TAM) receptor biology, which plays a vital role in modulating inflammation and immune responses. Illimis Therapeutics CEO Sanghoon Park stated: "This investment, government grants and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology. "We will continue to focus on innovative new drug development centred around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D [research and development] collaboration models." DSC Investment senior managing director Yohan Kim stated: "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs.' In October 2024, the company collaborated with Lilly Catalyze360-ExploR&D, part of Lilly's commitment towards external innovation, focusing on neurodegenerative disease applications. Under this partnership, the companies have been cooperating to advance the platform construct for neurodegenerative disease applications. "Illimis secures funding for GAIA-based Alzheimer's therapeutics" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
12-06-2025
- Business
- Business Wire
PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as 'the Company' or 'PHAXIAM,' a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025. As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets. The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator. Following this decision, PHAXIAM Therapeutics will request the delisting of its shares from Euronext, as previously announced. PHAXIAM reiterates that no reimbursement to shareholders can be made. Despite the efforts undertaken by the Company and its management to extend its financing horizon and maintain its operations, extremely challenging market conditions—particularly for small-cap listed biotech companies—did not allow for the implementation of a viable refinancing solution, leading the Company to file for receivership in early March 2025. Since 2017, PHAXIAM has provided more than 140 patients with phage-based treatments produced under pharmaceutical-grade standards, within a compassionate use framework. The Company sincerely hopes that these patients will continue to receive appropriate medical care and support despite the cessation of its activities. PHAXIAM would like to express its deep gratitude to all its stakeholders – including employees, partners, healthcare professionals, and shareholders – for their dedication and support throughout its journey. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Yahoo
02-06-2025
- Business
- Yahoo
Massachusetts Innovation Network Announces the 2025 Eddies Finalists
BURLINGTON, Mass., June 02, 2025--(BUSINESS WIRE)--Selected by nearly 40 independent Judges, Eddies Finalists spend 5 months engaging in a no-cost, no-equity program offering tailored mentoring, strategic guidance, leadership development, and access to funding and other resources. BiotechHill Research — generative AI accelerating clinical trial cycles, streamlining trial operations, and significantly increasing drug approval success Therapeutics — optimizes bio-active molecules from venom and animal toxins to develop innovative peptide therapeutics for medical Oncology —precision oncology, leveraging next-generation antibody-drug conjugates to develop therapies for lethal, currently incurable solid Therapeutics —innovative discovery and AI platform that designs novel small-molecule drugs targeting mRNA of cancer- and Alzheimer's- associated genes. CleantechLoopCO2 — Uses 29% CO₂ by weight, converting it into cosmetic oil, adhesives, and thermoplastic — Electrification of personal watercraft; eSkis deliver long battery life, rapid acceleration, and quiet rides for a greener CMC — Moving thin, thermally conductive dielectric ceramic sheets from 2D to 3D for thermal management parts and Bio —synthetic biology transforming food waste into high-value chemicals (mostly sugar polymers), at lower cost and reduced environmental impact. DeeptechLiftLabs — Lineless, self-surfacing lobster trap system -triggered via phone- to eliminate whale entanglement and support sustainable Robotics —compact robot for large-scale solar installation with seamless workflow — Enhances MRI performance with metamaterials that double image quality and cut scan times by 40%. HealthtechEden on Earth — Platform combining AI and hospitality principles, to automate manual workflows within HIPAA —all-in-one VR platform delivering calming, effective care with measurable clinical and economic HealthLink — AI-powered PPG imaging with any camera to measure vital signs in seconds for no-contact, remote health monitoring. Medical DevicesHighland Instruments —non-invasive brain stimulation platform combining electromagnetic and ultrasonic fields to treat chronic pain, Parkinson's, and —upper-limb therapy robot using air-cushion support and adaptive force feedback for stroke and TBI —ingestible capsule enabling precise, non-invasive small intestine sampling for gut diagnostics and therapeutics. Minority OwnedSKIP IT. — Content-filtering tool that automatically skips triggering or distressing movie and TV show scenes for safer, mindful Moon Automation — Smart farming equipment enabling growers to tend individual plants for healthier, more profitable Otter — Converts toxic PFAS waste into clean fuel and water through chemical conversion, reducing GHG emissions and landfill use. View source version on Contacts Sophia Kambanis(SophiaK@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity through 2044 with subsequent opportunity for patent term extension New U.S. patent granted after accelerated examination process covers the active polymorph of varoglutamstat, Vivoryon's lead drug in development Additional patents for medical use and dosing regimens under examination for varoglutamstat and related structures in kidney disease as monotherapy and in combination with SGLT-2 inhibitors Halle (Saale) / Munich, Germany, May 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent covering the Company's lead drug in development, varoglutamstat. The new patent was granted after an accelerated examination process. 'Vivoryon pursues a diligent and comprehensive strategy to continuously strengthen the intellectual property protecting our key assets on multiple levels. This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset varoglutamstat and is an important milestone for Vivoryon. The fact that it has been granted several months ahead of the anticipated timing is a testament to the outstanding work of our team,' said Frank Weber, MD, CEO of Vivoryon. 'We expect that this long patent runway will support our efforts to maximize the full therapeutic potential of varoglutamstat, which we plan to develop in kidney disease.' The newly granted composition of matter US patent (US 12,312,335) covers the only polymorph of the salt form used in the drug product of Vivoryon's unique QPCT/L inhibitor varoglutamstat. The patent has a scheduled runtime through 2044, with the subsequent opportunity for a patent term extension of up to five years to 2049 under the Hatch-Waxman Act. In addition, the Company has filed a number of different patents in its focus area of kidney disease over the past months. These relate to varoglutamstat and related structures, covering medical use, and dosing regimens, both as monotherapy and in combination with standard of care, namely SGLT-2 inhibitors. Adding an additional layer of protection, the patent applications cover the free base and all salt forms of varoglutamstat and are currently under examination. Vivoryon has a strong patent portfolio for QPTC/L inhibition and continues to evolve its IP strategy based on scientific evidence, striving to bolster its IP portfolio on multiple levels. Patent applications and granted patents span composition of matter, medical use as well as indications and dosing regimens. Recent additions to the portfolio relate to the Company's primary field of focus, diseases of the kidney and include patents for the combination of QPCT/L inhibitors with standard of care, SGLT-2 inhibitors. These patents were filed based on the outstanding effect observed in preclinical research, where data revealed synergistic effect of the combination treatment with varoglutamstat and an SGLT-2 inhibitor with both once and twice daily treatment. The Company has a strong patent portfolio relating to QPCT/L inhibitors in a broad range of diseases with high medical need, including kidney diseases, inflammatory diseases, oncology, genetic and fibrotic diseases. The portfolio is comprised of over 20 patent families and over 400 patent applications and issued patents covering all major markets, with composition of matter patents on QPCT/L inhibitors representing the clear majority and with recent patent applications reflecting Vivoryon's focus on kidney diseases. ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 250527_VVY US Patent Press Release_FINError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
